Federal contract award
75A50122C00065
TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $839.9M |
| Current contract value | $839.9M |
| Potential contract value / ceiling | $982.7M |
| Start date | Sep 30, 2022 |
| Current end date | Sep 29, 2032 |
| Potential end date | Sep 29, 2032 |
| Latest award activity | Aug 4, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 9 of 9 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 4, 2026 | P00008 | $66.0M | EO14398 FOR FAR 52.222-90, UPDATED HHSAR AND EXERCISE OPTION PERIOD 4A FOR $65,698,998.00 |
| Mar 6, 2026 | P00007 | $60.0M | EXERCISE OPTION PERIOD 4 AND MODIFY THE NUMBER OF DOSES. CHANGE THE PERIOD OF PERFORMANCE TO MARCH 4, 2026 THROUGH SEPTEMBER 29, 2032. THE TOTAL CONTRACT FUNDED VALUE INCREASED FROM $713,890,168.42 BY $59,988,838.10 TO $773,879,006.52. |
| Jul 15, 2025 | P00006 | $90.0M | EXERCISE OPTION PERIOD 3 CLINS 0010, 0011, AND 0012. |
| Sep 27, 2024 | P00005 | $0 | REVISE OPTION PERIOD 2 CLINS 0007 - 0009 PERIOD OF PERFORMANCE. |
| Sep 18, 2024 | P00004 | $129.0M | EXERCISE OPTION PERIOD 2 CLINS 0007 - 0009 FOR THE PROCUREMENT OF 62,896 UNITS OF NPLATE PHARMACEUTICAL PRODUCTS. |
| Feb 5, 2024 | P00003 | $0 | NO COST MODIFICATION TO REVISE SECTION B.2.2, CLIN TABLE DESCRIPTION COLUMN FOR CLIN0005. |
| Sep 20, 2023 | P00002 | $204.9M | AMGEN - EXERCISE OPTIONAL CLINS 0004, 0005, AND 0006. ADD FAR CLAUSE 52.204-27. |
| Dec 12, 2022 | P00001 | $0 | AMGEN - UNILATERAL MODIFICATION TO REVISE THE CONTRACTING OFFICER. |
| Sep 28, 2022 | 0 | $290.1M | TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. |
Estimated positioning window
Sep 29, 2031 – Mar 29, 2032
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2032-09-29 (2166 days from calculation)
- +5 points
- 121 historical awards in this buyer and category group
- +15 points
- 9 recorded award transactions
- +10 points
- Latest award action: 2026-08-04
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Richard Hall | Contact | Richard.Hall@hhs.gov | Source | Aug 16, 2022 |
| Jonathan Gonzalez | Contact | Jonathan.Gonzalez@hhs.gov | Source | Aug 16, 2022 |
| Richard Hall | Contact | Richard.Hall@hhs.gov | Source | Aug 12, 2022 |
| Jonathan Gonzalez | Contact | Jonathan.Gonzalez@hhs.gov | Source | Aug 12, 2022 |
| Richard Hall | Contact | Richard.Hall@hhs.gov | Source | Jul 27, 2022 |
| Jonathan Gonzalez | Contact | Jonathan.Gonzalez@hhs.gov | Source | Jul 27, 2022 |
| Richard Hall | Contact | Richard.Hall@hhs.gov | Source | Jul 26, 2022 |
| Jonathan Gonzalez | Contact | Jonathan.Gonzalez@hhs.gov | Source | Jul 26, 2022 |
| Richard Hall | Contact | Richard.Hall@hhs.gov | Source | Jun 15, 2022 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.